Mometasone furoate nasal spray was more effective for symptom relief of acute rhinosinusitis than amoxicillin or placebo

doi:10.1136/ebm.11.4.114

HOME

Author	Keyword(s)
Vol	Page
[Advanced]

Evidence-Based Medicine 2006;11:114; doi:10.1136/ebm.11.4.114
Copyright © 2006 by the BMJ Publishing Group Ltd.

This Article

	Full Text
	Full Text (PDF)
	Submit a response
	Alert me when this article is cited
	Alert me when eLetters are posted
	Alert me if a correction is posted

Services

	Email this article to a friend
	Similar articles in this journal
	Similar articles in PubMed
	Add article to my folders
	Download to citation manager
	Request Permissions

Citing Articles

	Citing Articles via Google Scholar

Google Scholar

	Articles by Lindbæk, M.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Lindbæk, M.

Topic Collections

	Related Article

Therapeutics

Mometasone furoate nasal spray was more effective for symptom relief of acute rhinosinusitis than amoxicillin or placebo

Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol 2005;116:1289–95.[CrossRef][Medline]

Q In patients with acute, uncomplicated rhinosinusitis lasting $>=$ 7 days, what is the relative effectiveness of mometasone furoate nasal spray, amoxicillin, and placebo?

Clinical impact ratings GP/FP/Primary care $*$ $*$ $*$ $*$ $*$ ${star}$ ${star}$ Allergy & immunology $*$ $*$ $*$ $*$ $*$ ${star}$ ${star}$ Respirology $*$ $*$ $*$ $*$ $*$ ${star}$ ${star}$

Key Words: rhinitis • sinusitis • pregnadienediols • amoxicillin

The first 150 words of the full text of this article appear below.

METHODS
Design: randomised controlled trial.

Allocation: unclear allocation concealment.^*

Blinding: blinded (patients and healthcare providers).^*

Follow up period: up to 29 days.

Setting: 71 medical centres in 14 countries.

Patients: 981 patients $>=$ 12 years of age (mean age 35 y, 66% women) withsigns and symptoms of acute rhinosinusitis for $>=$ 7 days but $<=$ 28days and major symptom score (MSS) $>=$ 5 but $<=$ 12, with $<=$ 3 of 5 symptomsrated as severe (based on the sum of scores for rhinorrhoea,postnasal drip, nasal congestion/stuffiness, sinus headache,and facial pain/pressure/tenderness).

Intervention: mometasone furoate nasal spray, 200 µg, once daily for15 days (n = 243); mometasone spray, 200 µg, twice dailyfor 15 days (n = 235); amoxicillin, 500 mg, 3 times daily for10 days (n = 251); or placebo (n = 252).

Outcomes: main outcome was mean MSS over days 2–15 (treatment phase).Secondary outcomes included mean total symptom score, individual. . . [Full text of this article]

Morten Lindbæk, MD

University of Oslo, Oslo, Norway

Related Article

Glossary
Evid. Based Med. 2006 11: 127. (in Glossary) [Extract] [Full Text] [PDF]